HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Granulosa-cell and theca-cell tumors. The clinical picture and long-term outcome for the Radiumhemmet series.

Abstract
Over the period 1923--72 a total of 305 patients with granulosa-cell, theca-cell tumor and mixed tumor were seen at Radiumhemmet. The commonest symptom was abnormal uterine bleeding. Twenty-three per cent of married women were nulliparous. The menarche seems to have occurred earlier in this group than in the general population. Eight of the granulosa-cell tumor group gave birth to 12 children after treatment for the tumor. Nineteen women with granulosa-cell tumor and 4 with thecoma had received radiotherapy earlier in life for benign lesions. The risk of endometrial cancer was approximately 10 times greater for the women with granulosa- or theca-cell tumor than for the general population. Two hundred and fifty-two patients were given both surgical treatment and radiotherapy. Fifty-three received only surgery (37 granulosa-cell and 16 theca-cell tumors). None of the thecoma patients but 21 per cent of those with granulosa-cell tumor died from their disease. The 5-year survival for the latter group, all stages, was 85 per cent.
AuthorsE Björkholm, F Pettersson
JournalActa obstetricia et gynecologica Scandinavica (Acta Obstet Gynecol Scand) Vol. 59 Issue 4 Pg. 361-5 ( 1980) ISSN: 0001-6349 [Print] United States
PMID6255725 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Female
  • Follow-Up Studies
  • Granulosa Cell Tumor (mortality, therapy)
  • Humans
  • Menarche
  • Menopause
  • Middle Aged
  • Ovarian Neoplasms (mortality, therapy)
  • Parity
  • Prognosis
  • Sweden
  • Thecoma (mortality, therapy)
  • Uterine Hemorrhage (complications)
  • Uterine Neoplasms (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: